Nothing Special   »   [go: up one dir, main page]

BR112012008173A2 - molécula de ligação específica de rsv - Google Patents

molécula de ligação específica de rsv

Info

Publication number
BR112012008173A2
BR112012008173A2 BR112012008173A BR112012008173A BR112012008173A2 BR 112012008173 A2 BR112012008173 A2 BR 112012008173A2 BR 112012008173 A BR112012008173 A BR 112012008173A BR 112012008173 A BR112012008173 A BR 112012008173A BR 112012008173 A2 BR112012008173 A2 BR 112012008173A2
Authority
BR
Brazil
Prior art keywords
specific binding
binding molecule
rsv
antibody
rsv specific
Prior art date
Application number
BR112012008173A
Other languages
English (en)
Other versions
BR112012008173B1 (pt
Inventor
Quirinus Bakker Adrianus
Yasuda Etsuko
Beaumont Tim
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112012008173A2 publication Critical patent/BR112012008173A2/pt
Publication of BR112012008173B1 publication Critical patent/BR112012008173B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

molécula de ligação específica de rsv. a invenção fornece anticorpos e equivalentes funcionais dos mesmos que são capazes de ligar especificamente rsv. as sequências de ácido nucleico que encodifica o dito anticorpo, bem como a célula que produz anticorpos e métodos para produzir o dito anticorpo também são fornecidos.
BR112012008173-0A 2009-10-06 2009-10-06 Anticorpo monoclonal humano recombinante, sintético ou isolado ou uma parte funcional do mesmo que se liga especificamente à proteína f do vírus sincicial respiratório, sequência de ácido nucleico isolada ou um equivalente funcional da mesma, vetor, combinação, composição farmacêutica, usos dos mesmos e método para produzir um anticorpo ou parte funcional do mesmo BR112012008173B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2009/050599 WO2011043643A1 (en) 2009-10-06 2009-10-06 Rsv-specific binding molecule

Publications (2)

Publication Number Publication Date
BR112012008173A2 true BR112012008173A2 (pt) 2017-10-10
BR112012008173B1 BR112012008173B1 (pt) 2021-12-07

Family

ID=42153917

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008173-0A BR112012008173B1 (pt) 2009-10-06 2009-10-06 Anticorpo monoclonal humano recombinante, sintético ou isolado ou uma parte funcional do mesmo que se liga especificamente à proteína f do vírus sincicial respiratório, sequência de ácido nucleico isolada ou um equivalente funcional da mesma, vetor, combinação, composição farmacêutica, usos dos mesmos e método para produzir um anticorpo ou parte funcional do mesmo

Country Status (14)

Country Link
EP (1) EP2486053B1 (pt)
JP (1) JP5734988B2 (pt)
KR (1) KR101789343B1 (pt)
CN (1) CN102712692B (pt)
AU (1) AU2009353693B2 (pt)
BR (1) BR112012008173B1 (pt)
CA (1) CA2776249C (pt)
ES (1) ES2621458T3 (pt)
IL (1) IL219021A (pt)
MX (1) MX338063B (pt)
NZ (1) NZ599148A (pt)
RU (2) RU2540020C2 (pt)
WO (1) WO2011043643A1 (pt)
ZA (1) ZA201202502B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
BRPI0911431B8 (pt) 2008-04-11 2021-05-25 Chugai Pharmaceutical Co Ltd composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
CA2768207C (en) 2009-07-15 2019-12-03 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
WO2012072814A1 (en) * 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US9718876B2 (en) 2011-11-17 2017-08-01 Aimm Therapeutics B.V. RSV G protein specific antibodies
HK1198771A1 (en) 2011-11-30 2015-06-05 中外制药株式会社 Drug containing carrier into cell for forming immune complex
WO2013118858A1 (ja) 2012-02-09 2013-08-15 中外製薬株式会社 抗体のFc領域改変体
EP3721900A1 (en) 2012-08-24 2020-10-14 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc region variant
DK2950886T3 (da) 2013-02-01 2020-03-23 Medimmune Llc Respiratorisk syncytialvirus-f-protein-epitoper
DK2970398T3 (da) 2013-03-13 2024-08-05 Us Health Præfusions-rsv-f-proteiner og anvendelse deraf
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US9856313B2 (en) 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
EP3094353B1 (en) 2014-01-15 2020-04-01 Medlmmune, LLC Rsv-specific antibodies and functional parts thereof
JP6747975B2 (ja) 2014-01-31 2020-08-26 アイム・セラピューティクス・べー・フェー 安定な抗体を産生するための手段及び方法
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
RU2713340C1 (ru) * 2018-12-28 2020-02-04 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам респираторно-синцитиального вируса
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
WO2004043989A2 (en) * 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
AU2005214988A1 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2008295248A1 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-RSV antibodies
WO2009114815A1 (en) * 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs

Also Published As

Publication number Publication date
RU2014151788A (ru) 2016-07-10
RU2540020C2 (ru) 2015-01-27
MX338063B (es) 2016-04-01
CN102712692A (zh) 2012-10-03
CA2776249A1 (en) 2011-04-14
RU2014151788A3 (pt) 2018-07-09
NZ599148A (en) 2014-08-29
EP2486053B1 (en) 2017-01-18
JP5734988B2 (ja) 2015-06-17
EP2486053A1 (en) 2012-08-15
WO2011043643A1 (en) 2011-04-14
CA2776249C (en) 2021-01-19
AU2009353693A1 (en) 2012-04-19
MX2012004086A (es) 2012-09-12
ZA201202502B (en) 2014-06-25
KR101789343B1 (ko) 2017-10-23
ES2621458T3 (es) 2017-07-04
RU2012118636A (ru) 2013-11-20
JP2013506431A (ja) 2013-02-28
CN102712692B (zh) 2014-12-31
KR20120084755A (ko) 2012-07-30
AU2009353693B2 (en) 2016-07-21
BR112012008173B1 (pt) 2021-12-07
IL219021A0 (en) 2012-06-28
IL219021A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
BR112012008173A2 (pt) molécula de ligação específica de rsv
BRPI0923225A2 (pt) metodo para sintese de acidos nucleicos modificados no atomo de fosforo
MX350375B (es) Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas.
BRPI0807756A2 (pt) Método para produzir um l-aminoácido.
BRPI0915886A2 (pt) método para amplificação direta a partir de amostras brutas de ácido nucléico
DK2121908T3 (da) Nukleinsyremolekyler, der koder for trunkeret alternansucrase
BRPI0822099A2 (pt) membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
FI20085336L (fi) Menetelmä muurahaishapon talteenottamiseksi
EA201171325A1 (ru) Нуклеиновые кислоты, связывающиеся с гепсидином
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
EA201400709A1 (ru) Молекула биспецифического антитела
BRPI0906544A2 (pt) método de obtenção de informação a partir de células isoladas de interesse.
UY31904A (es) Anticuerpos contra il-6 y sus usos
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
EP2613933A4 (en) HARDENABLE HOLDING SYSTEM AND METHOD FOR MOUNTING DIFFERENT COMPONENTS THEREWITH
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
EP2315619A4 (en) PROCESS FOR EXTRACTING NUCLEIC ACIDS
BRPI0813764A2 (pt) Processo para formação de haletos de carbonila alfa, beta-insaturados
HRP20151054T1 (xx) Postupak proizvodnje faktora vii bez seruma, bez inzulina
BRPI0909771A2 (pt) processo para preparar ácido cianídrico
BRPI0920435A2 (pt) processo para produzir gás de síntese de amônia.
DK2370206T3 (da) Katalysatorbærer, fremgangsmåde til fremstilling og anvendelse af denne

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.